HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

AhR and Arnt differentially regulate NF-κB signaling and chemokine responses in human bronchial epithelial cells.

AbstractBACKGROUND:
The aryl hydrocarbon receptor (AhR) has gradually emerged as a regulator of inflammation in the lung and other tissues. AhR may interact with the p65-subunit of the nuclear factor (NF)-κB transcription factors, but reported outcomes of AhR/NF-κB-interactions are conflicting. Some studies suggest that AhR possess pro-inflammatory activities while others suggest that AhR may be anti-inflammatory. The present study explored the impact of AhR and its binding partner AhR nuclear translocator (Arnt) on p65-activation and two differentially regulated chemokines, CXCL8 (IL-8) and CCL5 (RANTES), in human bronchial epithelial cells (BEAS-2B).
RESULTS:
Cells were exposed to CXCL8- and CCL5-inducing chemicals, 1-nitropyrene (1-NP) and 1-aminopyrene (1-AP) respectively, or the synthetic double-stranded RNA analogue, polyinosinic-polycytidylic acid (Poly I:C) which induced both chemokines. Only CXCL8, and not CCL5, appeared to be p65-dependent. Yet, constitutively active unligated AhR suppressed both CXCL8 and CCL5, as shown by siRNA knock-down and the AhR antagonist α-naphthoflavone. Moreover, AhR suppressed activation of p65 by TNF-α and Poly I:C as assessed by luciferase-assay and p65-phosphorylation at serine 536, without affecting basal p65-activity. In contrast, Arnt suppressed only CXCL8, but did not prevent the p65-activation directly. However, Arnt suppressed expression of the NF-κB-subunit RelB which is under transcriptional regulation by p65. Furthermore, AhR-ligands alone at high concentrations induced a moderate CXCL8-response, without affecting CCL5, but suppressed both CXCL8 and CCL5-responses by Poly I:C.
CONCLUSION:
AhR and Arnt may differentially and independently regulate chemokine-responses induced by both inhaled pollutants and pulmonary infections. Constitutively active, unligated AhR suppressed the activation of p65, while Arnt may possibly interfere with the action of activated p65. Moreover, ligand-activated AhR suppressed CXCL8 and CCL5 responses by other agents, but AhR ligands alone induced CXCL8 responses when given at sufficiently high concentrations, thus underscoring the duality of AhR in regulation of inflammation. We propose that AhR-signaling may be a weak activator of p65-signaling that suppresses p65-activity induced by strong activators of NF-κB, but that its anti-inflammatory properties also are due to interference with additional pathways.
AuthorsJohan Øvrevik, Marit Låg, Valerie Lecureur, David Gilot, Dominique Lagadic-Gossmann, Magne Refsnes, Per E Schwarze, Tonje Skuland, Rune Becher, Jørn A Holme
JournalCell communication and signaling : CCS (Cell Commun Signal) Vol. 12 Pg. 48 (Jul 24 2014) ISSN: 1478-811X [Electronic] England
PMID25201625 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • ARNT protein, human
  • Air Pollutants
  • Benzoflavones
  • CCL5 protein, human
  • CXCL8 protein, human
  • Chemokine CCL5
  • Interleukin-8
  • NF-kappa B
  • Pyrenes
  • Receptors, Aryl Hydrocarbon
  • Tumor Necrosis Factor-alpha
  • Aryl Hydrocarbon Receptor Nuclear Translocator
  • Serine
  • alpha-naphthoflavone
  • 1-aminopyrene
  • Poly I-C
  • 1-nitropyrene
Topics
  • Air Pollutants (pharmacology)
  • Aryl Hydrocarbon Receptor Nuclear Translocator (metabolism)
  • Benzoflavones (pharmacology)
  • Bronchi (cytology)
  • Cell Line, Tumor
  • Chemokine CCL5 (metabolism)
  • Epithelial Cells (drug effects, metabolism)
  • Humans
  • Interleukin-8 (metabolism)
  • NF-kappa B (metabolism)
  • Phosphorylation
  • Poly I-C (pharmacology)
  • Pyrenes (pharmacology)
  • Receptors, Aryl Hydrocarbon (antagonists & inhibitors, metabolism)
  • Serine (metabolism)
  • Signal Transduction
  • Tumor Necrosis Factor-alpha (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: